Lab
SSM Health Care of Wisconsin, INC
SSM Health Care of Wisconsin, INC was paid $6.40M by Medicaid between Jan 2018 and Dec 2024, across 112 billing codes. Its largest line is U0003, Infectious agent detection by nucleic acid (dna or rna); severe acute respiratory syndrome coronavirus 2 (sars-cov-2) (coronavirus disease [covid-19]), amplified probe technique, making use of high throughput technologies as described by cms-2020-01-r — 22% of everything it billed.
33Billing provider infoSSM HEALTH CARE OF WISCONSIN, INC
MADISON, WI 53715
MADISON, WI 53715
33aNPI1770597445assigned 07/28/2006
33bProvider typeClinical Medical Laboratory
28Total paid$6.40M
24GClaims345,775
24DCodes billed112
24AFirst – last monthJan 2018 – Dec 2024
Compared with peers
Next to other Clinical Medical Laboratory providers in Wisconsin
Rank by total paid#11 of 75
Median peer was paid$106K
This provider vs. median60×
Peers share this provider's primary NPPES type and state. Size alone says nothing about billing quality: a big agency or a hospital system is expected to sit far above the median.
Box 24A · Dates of service
Paid by month
Paid that monthNov–Dec 2024: claims still arriving when the file was cut, so these months run low for every provider
By year, as a table
| Year | Claims | Paid | |
|---|---|---|---|
| 2018 | 24,625 | $555K | |
| 2019 | 29,833 | $475K | |
| 2020 | 50,388 | $890K | |
| 2021 | 70,084 | $1.51M | |
| 2022 | 64,327 | $1.40M | |
| 2023 | 59,075 | $908K | |
| 2024incomplete | 47,443 | $660K |
Box 24 · Service lines
What it billed for
| Code | Service | Share | Claims | Bene. records | Paid |
|---|---|---|---|---|---|
| U0003 | Infectious agent detection by nucleic acid (dna or rna); severe acute respiratory syndrome coronavirus 2 (sars-cov-2) (coronavirus disease [covid-19]), amplified probe technique, making use of high throughput technologies as described by cms-2020-01-r | 22% | 17,137 | 15,687 | $1.43M |
| 87491 | Infectious agent detection by nucleic acid; Chlamydia trachomatis, amplified probe | 10% | 21,464 | 18,459 | $668K |
| 87591 | Infectious agent detection by nucleic acid; Neisseria gonorrhoeae, amplified probe | 10% | 21,468 | 18,445 | $668K |
| 88305 | Level IV - Surgical pathology, gross and microscopic examination | 3.9% | 11,998 | 6,250 | $247K |
| 84443 | Thyroid stimulating hormone (TSH) | 3.6% | 16,027 | 14,513 | $230K |
| 87637 | Infectious agent detection by nucleic acid; SARS-CoV-2, influenza, and RSV | 3.4% | 2,113 | 2,003 | $218K |
| 82306 | Vitamin D; 25 hydroxy, includes fraction(s), if performed | 3.1% | 7,543 | 6,922 | $196K |
| 80053 | Comprehensive metabolic panel | 3.0% | 19,889 | 17,873 | $191K |
| 87636 | Infectious agent detection by nucleic acid; SARS-CoV-2 and influenza virus types A and B | 3.0% | 1,888 | 1,768 | $191K |
| 80061 | Lipid panel | 2.5% | 14,615 | 13,240 | $161K |
| 87389 | Infectious agent antigen detection by immunoassay technique, HIV-1 antigen with HIV-1 and HIV-2 antibodies | 2.5% | 8,161 | 7,067 | $161K |
| 87624 | Infectious agent detection by nucleic acid; human papillomavirus (HPV), high-risk types | 2.3% | 6,492 | 4,922 | $150K |
100 more codes
| U0005 | Infectious agent detection by nucleic acid (dna or rna); severe acute respiratory syndrome coronavirus 2 (sars-cov-2) (coronavirus disease [covid-19]), amplified probe technique, cdc or non-cdc, making use of high throughput technologies, completed within 2 calendar days from date of specimen collection (list separately in addition to either hcpcs code u0003 or u0004) as described by cms-2020-01-r2 | 2.3% | 14,527 | $144K |
| 83036 | Hemoglobin; glycosylated (A1C) | 2.2% | 17,041 | $143K |
| 88142 | 2.0% | 8,674 | $127K | |
| 87086 | Culture, bacterial; quantitative colony count, urine | 1.3% | 11,290 | $85K |
| 87653 | 1.3% | 2,362 | $82K | |
| 82728 | 1.2% | 6,541 | $80K | |
| 86803 | 1.2% | 6,818 | $80K | |
| 80048 | Basic metabolic panel (calcium, ionized) | 1.1% | 9,569 | $72K |
| 87081 | <1% | 7,804 | $53K | |
| 87635 | Infectious agent detection by nucleic acid; SARS-CoV-2 (COVID-19), amplified probe | <1% | 1,063 | $51K |
| 82607 | <1% | 3,920 | $51K | |
| 87505 | <1% | 428 | $49K | |
| 84466 | <1% | 4,243 | $46K | |
| 84702 | <1% | 2,888 | $39K | |
| 86762 | <1% | 3,236 | $39K | |
| 87077 | <1% | 4,906 | $36K | |
| 87186 | <1% | 4,312 | $35K | |
| 80050 | General health panel | <1% | 732 | $34K |
| 87340 | <1% | 3,805 | $31K | |
| 82746 | <1% | 2,236 | $27K | |
| 87661 | Infectious agent detection by nucleic acid; Trichomonas vaginalis, amplified probe | <1% | 1,039 | $26K |
| 83540 | <1% | 4,549 | $26K | |
| 84439 | <1% | 3,017 | $24K | |
| 88342 | <1% | 2,393 | $23K | |
| 84481 | <1% | 1,484 | $21K | |
| 87808 | <1% | 1,685 | $20K | |
| 87070 | <1% | 2,332 | $19K | |
| 86592 | <1% | 4,419 | $18K | |
| 86140 | <1% | 3,805 | $18K | |
| 82784 | <1% | 1,971 | $17K | |
| 84146 | <1% | 962 | $16K | |
| 86618 | <1% | 929 | $16K | |
| 87205 | <1% | 4,252 | $15K | |
| 80076 | <1% | 2,021 | $15K | |
| 87529 | <1% | 218 | $15K | |
| 86850 | <1% | 3,444 | $14K | |
| 83001 | <1% | 901 | $14K | |
| 85025 | Blood count; complete (CBC), automated, and automated differential WBC count | <1% | 2,081 | $14K |
| 86706 | <1% | 1,420 | $13K | |
| 82043 | <1% | 2,672 | $13K | |
| 82570 | <1% | 2,829 | $12K | |
| 85027 | <1% | 1,979 | $11K | |
| 85610 | <1% | 3,121 | $11K | |
| 83880 | <1% | 362 | $11K | |
| 81401 | <1% | 88 | $11K | |
| 83970 | <1% | 294 | $10K | |
| G0103 | Prostate cancer screening; prostate specific antigen test (psa) | <1% | 635 | $10K |
| 86705 | <1% | 967 | $10K | |
| 82947 | <1% | 2,484 | $8K | |
| 86900 | <1% | 3,018 | $8K | |
| 86901 | <1% | 3,002 | $8K | |
| 86780 | <1% | 866 | $7K | |
| 86769 | <1% | 269 | $7K | |
| 83690 | <1% | 1,155 | $7K | |
| 83735 | <1% | 1,228 | $7K | |
| 82565 | <1% | 1,559 | $7K | |
| 87631 | <1% | 46 | $6K | |
| 88341 | <1% | 295 | $6K | |
| 84460 | <1% | 1,283 | $6K | |
| 86431 | <1% | 1,036 | $5K | |
| 87147 | <1% | 928 | $5K | |
| 84403 | <1% | 214 | $5K | |
| 87502 | Infectious agent detection by nucleic acid, influenza virus, for multiple types or subtypes, includes all targets | <1% | 47 | $4K |
| 84156 | <1% | 1,302 | $4K | |
| 84550 | <1% | 1,030 | $4K | |
| G0480 | Drug test(s), definitive, utilizing (1) drug identification methods able to identify individual drugs and distinguish between structural isomers (but not necessarily stereoisomers), including, but not limited to gc/ms (any type, single or tandem) and lc/ms (any type, single or tandem and excluding immunoassays (e.g., ia, eia, elisa, emit, fpia) and enzymatic methods (e.g., alcohol dehydrogenase)), (2) stable isotope or other universally recognized internal standards in all samples (e.g., to control for matrix effects, interferences and variations in signal strength), and (3) method or drug-specific calibration and matrix-matched quality control material (e.g., to control for instrument variations and mass spectral drift); qualitative or quantitative, all sources, includes specimen validity testing, per day; 1-7 drug class(es), including metabolite(s) if performed | <1% | 102 | $4K |
| 85652 | <1% | 1,538 | $4K | |
| 82274 | <1% | 262 | $3K | |
| 82670 | <1% | 123 | $3K | |
| 88304 | <1% | 168 | $3K | |
| 83655 | <1% | 197 | $2K | |
| 83002 | <1% | 139 | $2K | |
| 82550 | <1% | 314 | $2K | |
| 84450 | <1% | 356 | $1K | |
| 83615 | <1% | 243 | $1K | |
| 82247 | <1% | 291 | $1K | |
| 80177 | <1% | 82 | $1K | |
| 83718 | <1% | 150 | $1K | |
| 87798 | Infectious agent detection by nucleic acid; not otherwise specified, amplified probe, each organism | <1% | 26 | $912.34 |
| 88141 | <1% | 70 | $835.62 | |
| 87328 | <1% | 41 | $627.28 | |
| 82533 | <1% | 44 | $619.56 | |
| 81015 | <1% | 233 | $612.65 | |
| 87075 | <1% | 51 | $588.70 | |
| 82465 | <1% | 152 | $588.04 | |
| 86364 | <1% | 54 | $507.32 | |
| 84165 | <1% | 40 | $464.51 | |
| 81001 | <1% | 78 | $266.73 | |
| 87329 | <1% | 12 | $192.80 | |
| 82248 | <1% | 34 | $158.37 | |
| 86141 | <1% | 15 | $158.29 | |
| 82951 | <1% | 14 | $154.44 | |
| 87102 | <1% | 14 | $145.44 | |
| 86038 | <1% | 12 | $132.99 | |
| 88312 | <1% | 31 | $132.14 | |
| 88300 | <1% | 15 | $81.62 | |
| 86787 | <1% | 13 | $79.10 | |
| 85730 | <1% | 13 | $72.18 | |
| 82952 | <1% | 14 | $47.04 | |
| 0202U | Oncology (prostate), multianalyte, gene expression profiling | 0% | 13 | $0.00 |
Claims and beneficiary counts add up across code × month rows, so one patient seen every month counts many times. Rows with fewer than 12 claims are suppressed by HHS, so small lines can be missing.
From NPPES
Who's on the registration
Authorized officialMINERATH, JOSEPH (SYSTEM DIR OF GOV REIMBURSEMENT)
| Provider | Location | Paid |
|---|---|---|
| SSM Health Care of Wisconsin, INC. | Madison, WI | $14.70M |
| SSM Health Care of Wisconsin INC | Baraboo, WI | $9.78M |
| SSM Health Care of Wisconsin, INC. | Janesville, WI | $8.37M |
| Ripon Medical Center INC | Ripon, WI | $4.30M |
| Agnesian Healthcare INC | Fond Du Lac, WI | $2.25M |
| SSM Health Care of Wisconsin INC | Janesville, WI | $1.03M |
| Agnesian Healthcare INC | Fond Du Lac, WI | $172K |
Matched on the authorized-official name exactly as entered in NPPES. A common name can match unrelated people.